Aridis Pharma Ipo Lock Up

Aridis pharma ipo lock up

Aridis pharma ipo lock up

Get­ting ready for its first Phase III tri­al, Aridis Phar­ma is now turn­ing to pub­lic in­vestors to sup­port its pathogen-spe­cif­ic im­munother­a­pies in a mod­est $35 mil­lion IPO.

San Jose, CA-based Aridis joins an ever-grow­ing crowd of biotechs look­ing to cash in on the bull­ish sen­ti­ment on dis­play on Nas­daq.

Their pitch: a port­fo­lio of ful­ly hu­man mon­o­clon­al an­ti­bod­ies treat life-threat­en­ing in­fec­tions such as hos­pi­tal-ac­quired pneu­mo­nia (HAP) and ven­ti­la­tor-as­so­ci­at­ed pneu­mo­nia (VAP), de­vel­oped from a pro­pri­etary dis­cov­ery plat­form.

All three of Aridis’ clin­i­cal pro­grams tar­get HAP and VAP, dif­fer­ing on­ly in the pathogen that they tar­get.

With lead as­set AR-301, they are start­ing off with S.

Aridis Pharmaceuticals


AR-301 and an­oth­er Phase II drug, AR-101 hit­ting P. aerug­i­nosa, are the core as­sets of a joint ven­ture Aridis set up a few months ago with Shen­zhen He­palink Phar­ma­ceu­ti­cal, in­vest­ing $1 mil­lion — He­palink chipped in the oth­er $15 mil­lion — in which the Chi­nese part­ner would de­vel­op and seek ap­proval for the drugs in the coun­try.

He­palink’s US sub­sidiary is a ma­jor stock­hold­er of Aridis, com­mand­ing 17.8% of the stock, fol­lowed by founder and CEO Vu Truong at 15.1% and chair­man Er­ic Patzer at 13.7%.

Lyft's lockup period ends, shares hold steady

Oth­er in­vestors in­clude Pineworld Cap­i­tal and Efung Rui­bo. No­tably, Robert Cough­lin, pres­i­dent and CEO of Mass­Bio, al­so holds less than 1% of the shares.

Oth­er than di­rect­ly fund­ing the clin­i­cal tri­als, the biotech — to be list­ed as $ARDS — is al­so al­lo­cat­ing part of the raise for the man­u­fac­tur­ing of clin­i­cal sup­plies for use in the tri­als, ac­cord­ing to the S-1.

Aridis pharma ipo lock up